Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Metastatic Non-TCC Urothelial Carcinoma
NCT03430895Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2018
- Primary completion
- Feb 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in urothelial carcinoma (UC), sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03430895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430895.